APN raises FY 2027 guidance: EBITDA above ZAR 9bn, NHEPS growth over 50%
Aspen Pharmacare (APN) raised FY 2027 guidance, targeting EBITDA over ZAR 9 billion and NHEPS growth above 50%, alongside stronger free cash flow.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.